WO2003059375A1 - Complex therapy for tissue regeneration - Google Patents

Complex therapy for tissue regeneration Download PDF

Info

Publication number
WO2003059375A1
WO2003059375A1 PCT/JP2002/000297 JP0200297W WO03059375A1 WO 2003059375 A1 WO2003059375 A1 WO 2003059375A1 JP 0200297 W JP0200297 W JP 0200297W WO 03059375 A1 WO03059375 A1 WO 03059375A1
Authority
WO
WIPO (PCT)
Prior art keywords
cytophysiologically
active substance
cells
tissue regeneration
organ
Prior art date
Application number
PCT/JP2002/000297
Other languages
French (fr)
Japanese (ja)
Inventor
Yoshiki Sawa
Satoshi Taketani
Shigeru Miyagawa
Original Assignee
Cardio Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardio Incorporated filed Critical Cardio Incorporated
Priority to PCT/JP2002/000297 priority Critical patent/WO2003059375A1/en
Priority to AU2002226683A priority patent/AU2002226683A1/en
Priority to JP2003559536A priority patent/JPWO2003059375A1/en
Publication of WO2003059375A1 publication Critical patent/WO2003059375A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A composition and a kit for regenerating a biological organ and treating a disease. The composition contains a cytophysiologically active substance and cells which are in the state being suitable for transplantation into the heart. This kit consists of the cytophysiologically active substance, cells and an instruction. Moreover, a method for regenerating a biological organ and a method of treating a disease are provided. These methods involve the step of providing the cytophysiologically active substance and the step of providing cells. Thus, an injured biological organ can be regenerated without resort to organ transplantation or a support system with medical instruments. Namely, diseases such as heart infarction can be treated thereby.
PCT/JP2002/000297 2002-01-17 2002-01-17 Complex therapy for tissue regeneration WO2003059375A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/JP2002/000297 WO2003059375A1 (en) 2002-01-17 2002-01-17 Complex therapy for tissue regeneration
AU2002226683A AU2002226683A1 (en) 2002-01-17 2002-01-17 Complex therapy for tissue regeneration
JP2003559536A JPWO2003059375A1 (en) 2002-01-17 2002-01-17 Tissue regeneration combination therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2002/000297 WO2003059375A1 (en) 2002-01-17 2002-01-17 Complex therapy for tissue regeneration

Publications (1)

Publication Number Publication Date
WO2003059375A1 true WO2003059375A1 (en) 2003-07-24

Family

ID=11738141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/000297 WO2003059375A1 (en) 2002-01-17 2002-01-17 Complex therapy for tissue regeneration

Country Status (3)

Country Link
JP (1) JPWO2003059375A1 (en)
AU (1) AU2002226683A1 (en)
WO (1) WO2003059375A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006085697A1 (en) * 2005-02-14 2006-08-17 Japan Health Sciences Foundation Combination therapy for cerebrovascular disease using adrenomedulin with mesenchymal stem cell
JP2007537752A (en) * 2004-05-19 2007-12-27 ザ クリーブランド クリニック ファウンデーション Genetically modified cells for therapeutic applications
JP2011529946A (en) * 2008-08-05 2011-12-15 コアセラピクス エスエルユー Parenteral composition comprising microspheres having a diameter of 10 to 20 μm
US8513007B2 (en) 2009-08-28 2013-08-20 The Cleveland Clinic Foundation SDF-1 delivery for treating ischemic tissue
US8679477B2 (en) 2007-12-14 2014-03-25 The Cleveland Clinic Foundation Use of SDF-1 to mitigate scar formation
US9226978B2 (en) 2002-08-22 2016-01-05 The Cleveland Clinic Foundation Method of treating ischemic disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045775A1 (en) * 1998-03-09 1999-09-16 St. Elizabeth's Medical Center Compositions and methods for modulating vascularization
JP2001316285A (en) * 2000-05-01 2001-11-13 Yasuhiko Tabata Material for regeneration of tissue organ composed of cell and cell growth factor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387369B1 (en) * 1997-07-14 2002-05-14 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US7749215B1 (en) * 1998-02-05 2010-07-06 Biosense, Inc. Intracardiac cell delivery and cell transplantation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045775A1 (en) * 1998-03-09 1999-09-16 St. Elizabeth's Medical Center Compositions and methods for modulating vascularization
JP2001316285A (en) * 2000-05-01 2001-11-13 Yasuhiko Tabata Material for regeneration of tissue organ composed of cell and cell growth factor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DONALD ORLIC ET AL.: "Mobilized bone marrow cells repair the infarcted heart, improving function and survival", PROC. NATL. ACAD. SCI. USA, vol. 98, no. 18, August 2001 (2001-08-01), pages 10344 - 10349, XP002950780 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9226978B2 (en) 2002-08-22 2016-01-05 The Cleveland Clinic Foundation Method of treating ischemic disorders
JP2007537752A (en) * 2004-05-19 2007-12-27 ザ クリーブランド クリニック ファウンデーション Genetically modified cells for therapeutic applications
WO2006085697A1 (en) * 2005-02-14 2006-08-17 Japan Health Sciences Foundation Combination therapy for cerebrovascular disease using adrenomedulin with mesenchymal stem cell
US8679477B2 (en) 2007-12-14 2014-03-25 The Cleveland Clinic Foundation Use of SDF-1 to mitigate scar formation
JP2011529946A (en) * 2008-08-05 2011-12-15 コアセラピクス エスエルユー Parenteral composition comprising microspheres having a diameter of 10 to 20 μm
US8513007B2 (en) 2009-08-28 2013-08-20 The Cleveland Clinic Foundation SDF-1 delivery for treating ischemic tissue
US8513213B2 (en) 2009-08-28 2013-08-20 The Cleveland Clinic Foundation SDF-1 delivery for treating ischemic tissue
US8883756B2 (en) 2009-08-28 2014-11-11 Juventas Therapeutics, Inc. SDF-1 delivery for treating ischemic tissue
US9844581B2 (en) 2009-08-28 2017-12-19 The Cleveland Clinic SDF-1 delivery for treating ischemic tissue

Also Published As

Publication number Publication date
AU2002226683A1 (en) 2003-07-30
JPWO2003059375A1 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
WO2004009767A3 (en) Cell therapy for regeneration
WO2003082074A3 (en) Method and system for treating tissue swelling
PL1641918T3 (en) Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
DE69941903D1 (en) TREATMENT OF PATIENTS OBTAINING BONE MARROW TRANSPLANTATION OR TRANSPLANTATION OF PERIPHERAL BLOOD TEMM CELLS WITH ANTI-CD20 ANTIBODIES
WO2004003164A3 (en) Methods of organ regeneration
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
WO2007035843A3 (en) Methods and compositions for organ and tissue functionality
WO2003076604A3 (en) Surgical device for skin therapy or testing
WO2004104166A3 (en) Administration of hyaluronic acid to enhance the function of transplanted stem cells
ATE395924T1 (en) RESTORATION OF DESTROYED TISSUE USING MULTIPOTENT CELLS
WO2007070301A3 (en) Vascular graft sterilization and decellularization
NO20052949D0 (en) Implant containing cultured use cells and method of manufacture
MXPA02007137A (en) Liver tissue source.
WO2008006544A3 (en) Use of gelatin and a cross-linking agent for producing a cross-linking therapeutic composition
WO2003085092A3 (en) Cellular transplantation for heart regeneration
WO1994006449A3 (en) Morphogen-induced liver regeneration
EP1541157A4 (en) Method of treating biological tissue for transplantation by applying ultrahigh hydrostatic pressure
WO2003059375A1 (en) Complex therapy for tissue regeneration
WO2005047469A3 (en) PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
WO2002092013A3 (en) Methods for treating liver disease and liver damage with growth hormone and foxm1b
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
WO2001094586A3 (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
JP2004533288A5 (en)
DE602005025341D1 (en) METHOD FOR SELECTIVELY EXPANDING, SELECTING AND ADDRESSING STRAIN OR BZW. Progenitor Cells-POPULATIONS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003559536

Country of ref document: JP

122 Ep: pct application non-entry in european phase